Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.

by Afschin Gandjour
Published 2020-01-01

Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG

by Afschin Gandjour
Published 2020-04-01

A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency

by Afschin Gandjour
Published 2020-03-01

Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results

by Afschin Gandjour, George Vousden
Published 2020-01-01

To Treat or Not to Treat? Cost-Effectiveness of Ace Inhibitors in Non-Diabetic Advanced Renal Disease - a Dutch Perspective

by Charles Christian Adarkwah, Afschin Gandjour, Maren Akkerman, Silvia Evers
Published 2013-05-01

Costs of patients with chronic kidney disease in Germany.

by Afschin Gandjour, Wencke Armsen, Wolfgang Wehmeyer, Jan Multmeier, Ulrich Tschulena
Published 2020-01-01

Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model.

by Charles Christian Adarkwah, Afschin Gandjour, Maren Akkerman, Silvia M Evers
Published 2011-01-01